Nafamostat reduces systemic inflammation in TLR7-mediated virus-like illness
Research
[키워드] addition
administration
Analysis
animal model
anti-inflammatory actions
anti-inflammatory effect
Anti-viral
behavioural
Blood
Brain
circulating leukocytes
CNS
collected
COVID-19
CXCL1
CXCL10
cytokine production
DMSO
evaluated
evidenced
examined
Exogenous
expression
had no
host response
IFN-γ
immunohistochemistry
immunomodulatory effects
increased expression
induce
Inflammation
Inflammatory response
inhibit
inhibiting
injection
Intravenous injection
liver
lung
marker
mice
nafamostat
pathology
phenotype
provide
qPCR
reduce
reducing
restored
Result
robust
serine protease inhibitor
shown
Sickness
Sickness behaviour
significantly
ssRNA
suppressed
systemic inflammation
temperature
TLR7/8
TMPRSS2
TNF
Treatment
treatment for COVID-19
turn
viral cell
viral infection
virus
virus infection
was determined
[DOI] 10.1186/s12974-021-02357-y PMC 바로가기 [Article Type] Research
[DOI] 10.1186/s12974-021-02357-y PMC 바로가기 [Article Type] Research